Skip to main content
Log in

Antifungal prophylaxis: update on an old strategy

  • Letter to the Editor
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Lagunes L, Rello J (2016) Invasive candidiasis: from mycobiome to infection, therapy, and prevention. Eur J Clin Microbiol Infect Dis. doi:10.1007/s10096-016-2658-0

    Google Scholar 

  2. Cortegiani A, Russotto V, Maggiore A et al (2016) Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 1:CD004920. doi:10.1002/14651858

    PubMed  Google Scholar 

  3. Cornely OA, Bassetti M, Calandra T et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37

    Article  CAS  PubMed  Google Scholar 

  4. Shorr AF, Chung K, Jackson WL et al (2005) Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 33:1928–1935, quiz 1936

    Article  CAS  PubMed  Google Scholar 

  5. Cortegiani A, Russotto V, Raineri SM, Giarratano A (2016) The paradox of the evidence about invasive fungal infection prevention. Crit Care 20:114. doi:10.1186/s13054-016-1284-7

    Article  PubMed  PubMed Central  Google Scholar 

  6. Karageorgopoulos DE, Vouloumanou EK, Ntziora F et al (2011) β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 52:750–770

    Article  CAS  PubMed  Google Scholar 

  7. Posteraro B, Tumbarello M, De Pascale G, et al. (2016) (1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. J Antimicrob Chemother

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A. Cortegiani.

Ethics declarations

Conflict of interest

AC, VR, and SMR declare that they have no competing interests. AG received grants, fees for educational presentation, and advisory board membership, without any relationship to the submitted work, from Pfizer (New York, NY, USA), Merck Sharp (Kenilworth, NJ, USA), and Gilead (Foster City, CA, USA). His institution received a grant from Gilead, Pfizer, and Merck Sharp without any relationship to the submitted work.

Ethical approval

This letter, given its nature, did not need to be approved by an ethical committee.

Informed consent

Patients were not involved; therefore, informed consent was not necessary. All the authors agreed in submitting the manuscript.

Funding

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cortegiani, A., Russotto, V., Raineri, S.M. et al. Antifungal prophylaxis: update on an old strategy. Eur J Clin Microbiol Infect Dis 35, 1719–1720 (2016). https://doi.org/10.1007/s10096-016-2699-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-016-2699-4

Keywords

Navigation